Published in F1000 Med Rep on May 08, 2009
Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med (1999) 7.41
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 6.54
Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med (2005) 5.17
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med (2003) 4.67
B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum (2004) 3.35
Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med (2004) 2.85
The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med (1994) 2.61
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum (2004) 2.23
Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum (2007) 2.03
The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev (1999) 1.88
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis (2006) 1.59
Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol (2001) 1.27
Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis (2007) 1.16
Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol (2008) 1.05
Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus (2000) 1.01
Can morbidity and mortality of SLE be improved? Best Pract Res Clin Rheumatol (2002) 0.96
Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. Rheumatology (Oxford) (2008) 0.91
B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child (2007) 0.90
New therapies in systemic lupus erythematosus - trials, troubles and tribulations.... working towards a solution. Lupus (2008) 0.89
EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. Ann Rheum Dis (2008) 0.87
Treating patients with lupus with B-cell depletion. Lupus (2008) 0.87
Clinical trial design in systemic lupus erythematosus. Curr Opin Rheumatol (2006) 0.79
B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum (2004) 3.35
Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest (2005) 2.55
Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol (2009) 2.05
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum (2012) 2.03
Lupus IgG VH4.34 antibodies bind to a 220-kDa glycoform of CD45/B220 on the surface of human B lymphocytes. J Immunol (2004) 1.18
B cell depletion therapy in autoimmune diseases. Front Biosci (2007) 1.15
Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum (2010) 1.13
B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol (2010) 1.13
B-cell-targeted therapy for systemic lupus erythematosus. Drugs (2006) 1.10
Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. J Immunol (2013) 1.01
Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther (2011) 1.00
NOTCH inhibits osteoblast formation in inflammatory arthritis via noncanonical NF-κB. J Clin Invest (2014) 0.96
Treatment targets in systemic lupus erythematosus: biology and clinical perspective. Arthritis Res Ther (2012) 0.90
B-cell biology and related therapies in systemic lupus erythematosus. Rheum Dis Clin North Am (2010) 0.89
Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche. J Immunol (2014) 0.86
New insights into B cell biology in systemic lupus erythematosus and Sjögren's syndrome. Curr Opin Rheumatol (2015) 0.86
Quantitative proteomics of parotid saliva in primary Sjögren's syndrome. Proteomics (2012) 0.79
Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome. Mult Scler (2008) 0.79
B cell immunology for the clinician. Pediatr Infect Dis J (2011) 0.75
Targeted biologic approaches to the treatment of systemic vasculitis. Clin Rev Allergy Immunol (2008) 0.75